{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:19:05Z","timestamp":1787624345065,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00210-026-05482-8","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T05:50:04Z","timestamp":1779688204000},"page":"16775-16782","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Datopotamab deruxtecan for endocrine-resistant HR-positive\/HER2-negative breast cancer: biological rationale and clinical evidence"],"prefix":"10.1007","volume":"399","author":[{"given":"Bhargavi","family":"Gumma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5196-8081","authenticated-orcid":false,"given":"Lohitha","family":"Gumma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"5482_CR1","doi-asserted-by":"publisher","unstructured":"Anderson KN, Schwab RB, Martinez ME (2014) Reproductive risk factors and BC subtypes: a review of the literature. Breast Cancer Res Treat 144(1):1\u201310. https:\/\/doi.org\/10.1007\/s10549\u2010014\u20102852\u20107","DOI":"10.1007\/s10549\u2010014\u20102852\u20107"},{"key":"5482_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2217\/fon-2023-0188","volume":"20","author":"A Bardia","year":"2024","unstructured":"Bardia A, Jhaveri K, Kalinsky K et al (2024) TROPION-Breast01: Dato-DXdvs chemotherapy in pre-treated inoperable or metastatic HR1\/HER2\u2013 BC. Future Oncol 20:423\u2013436","journal-title":"Future Oncol"},{"issue":"16","key":"5482_CR3","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/C8CS00676H","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh JD, Isidro-Llobet A, Parker JS, Spring DR (2019) Cleavable linkers in antibody drug conjugates. Chem Soc Rev 48(16):4361\u20134374","journal-title":"Chem Soc Rev"},{"issue":"5","key":"5482_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corva\u00efa N (2017) Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 16(5):315\u2013337. https:\/\/doi.org\/10.1038\/nrd.2016.268","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"5482_CR5","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung HYA, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"key":"5482_CR6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/14728222.2022.2113513","volume":"26","author":"M Cortesi","year":"2022","unstructured":"Cortesi M, Zanoni M, Maltoni R, Ravaioli S, Tumedei MM, Pirini F et al (2022) TROP2 (troph-oblast cell-surface antigen 2): a drug target for BC. Expert Opin Ther Targets 26:593\u2013602. https:\/\/doi.org\/10.1080\/14728222.2022.2113513","journal-title":"Expert Opin Ther Targets"},{"key":"5482_CR7","unstructured":"Daiichi-Sankyo (2025) DATOPOTAMAB DERUXTECAN\u00ae\u00a0approved in the U.S. for patients with previously treated metastatic HR positive, HER2 negative BC [media release]. 17 Jan\u00a0\u00a0https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202501\/20250117_E.pdf"},{"issue":"11","key":"5482_CR8","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1007\/s11095-015-1624-3","volume":"32","author":"M Damelin","year":"2015","unstructured":"Damelin M, Zhong W, Myers J, Sapra P (2015) Evolving strategies for target selection for antibody-drug conjugates. Pharm Res 32(11):3494\u20133507. https:\/\/doi.org\/10.1007\/s11095-015-1624-3","journal-title":"Pharm Res"},{"issue":"6","key":"5482_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S (2021) Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol 18(6):327\u2013344","journal-title":"Nat Rev Clin Oncol"},{"issue":"28","key":"5482_CR10","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.2217\/fon-2022-0407","volume":"18","author":"J Furlanetto","year":"2022","unstructured":"Furlanetto J, Marm\u00b4 e F, Loibl S (2022) Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon. Future Oncol Lond Engl 18(28):3199\u20133215. https:\/\/doi.org\/10.2217\/fon-2022-0407","journal-title":"Future Oncol Lond Engl"},{"key":"5482_CR11","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","volume":"24","author":"F Giugliano","year":"2022","unstructured":"Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G (2022) Bystander effect of antibody-drug conjugates: fact or fiction? Curr Oncol Rep 24:809","journal-title":"Curr Oncol Rep"},{"issue":"16","key":"5482_CR12","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1158\/1078-0432.CCR-15-1701","volume":"22","author":"E Guerra","year":"2016","unstructured":"Guerra E et al (2016) Trop-2 induces tumor growth through AKT and determines sensitivity to AKT inhibitors. Clin Cancer Res 22(16):4197","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5482_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F (2019) Breast cancer. Nat Rev Dis Primers 5(1):66. https:\/\/doi.org\/10.1038\/s41572-019-0111-2","journal-title":"Nat Rev Dis Primers"},{"key":"5482_CR14","unstructured":"https:\/\/fda.report\/DailyMed\/2950227c-6230-4ca4-a135-46e44d9424a0\/#section-12 [ Accessed on may 25,2025]"},{"key":"5482_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102670","volume":"123","author":"K Jhaveri","year":"2024","unstructured":"Jhaveri K, Marm\u00b4 e F (2024) Current and emerging treatment approaches for hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic BC. Cancer Treat Rev 123:102670","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"5482_CR16","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.annonc.2020.09.004","volume":"31","author":"K Kalinsky","year":"2020","unstructured":"Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O\u2019Shaughnessy J, Moroose RL, Mayer IA, Abramson VG, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Goswami T, Wegener WA, Bardia A (2020) Sacituzumab Govitecan in previously treated hormone receptor-positive\/HER2-negative metastatic BC: final results from a phase I\/II, single-arm, basket trial. Ann Oncol 31(12):1709\u20131718. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.004","journal-title":"Ann Oncol"},{"issue":"1","key":"5482_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","volume":"22","author":"A Kopp","year":"2023","unstructured":"Kopp A, Hofsess S, Cardillo TM, Govindan SV, Donnell J, Thurber GM (2023) Antibody-drug conjugate Sacituzumab Govitecan drives efficient tissue penetration and rapid intracellular drug release. Mol Cancer Ther 22(1):102\u2013111","journal-title":"Mol Cancer Ther"},{"key":"5482_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","volume":"69","author":"JM Lambert","year":"2018","unstructured":"Lambert JM, Berkenblit A (2018) Antibody\u2013drug conjugates for cancer treatment. Annu Rev Med 69:191\u2013207","journal-title":"Annu Rev Med"},{"key":"5482_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.breast.2023.02.003","volume":"68","author":"Y Lang","year":"2023","unstructured":"Lang Y, Chai Q, Tao W, Liao Y, Liu X, Wu B (2023) Cost-effectiveness of Sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative BC. Breast Edinb Scotl 68:173\u2013180. https:\/\/doi.org\/10.1016\/j.breast.2023.02.003","journal-title":"Breast Edinb Scotl"},{"key":"5482_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12935-022-02679-8","volume":"22","author":"HE Marei","year":"2022","unstructured":"Marei HE, Cenciarelli C, Hasan A (2022) Potential of antibody-drug conjugates (ADCs) for cancer therapy. Cancer Cell Int 22:255","journal-title":"Cancer Cell Int"},{"issue":"1","key":"5482_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13058-020-01284-9","volume":"22","author":"O Mart\u00ednez-S\u00e1ez","year":"2020","unstructured":"Mart\u00ednez-S\u00e1ez O, Chic N, Pascual T et al (2020) Frequency and spectrum of PIK3CA somatic mutations in BC. BC Res 22(1):45. https:\/\/doi.org\/10.1186\/s13058-020-01284-9","journal-title":"BC Res"},{"key":"5482_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3747\/co.25.4000","volume":"25","author":"M Matutino","year":"2018","unstructured":"Matutino M, Joy A, Brezden-Masley C et al (2018) Hormone receptor-positive, HER2-negative metastatic BC: redrawing the lines. Curr Oncol (Toronto, Ont) 25:131\u2013141","journal-title":"Curr Oncol (Toronto, Ont)"},{"issue":"12","key":"5482_CR23","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","volume":"20","author":"D Okajima","year":"2021","unstructured":"Okajima D, Yasuda S, Maejima T et al (2021) Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther 20(12):2329\u20132340","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"5482_CR24","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J et al (2017) 20\u2010year risks of breast\u2010cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836\u20131846. https:\/\/doi.org\/10.1056\/NEJMoa1701830","journal-title":"N Engl J Med"},{"key":"5482_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2021.111322","volume":"532","author":"F Rasha","year":"2021","unstructured":"Rasha F, Sharma M, Pruitt K (2021) Mechanisms of endocrine therapy resistance in BC. Mol Cell Endocrinol 532:111322. https:\/\/doi.org\/10.1016\/j.mce.2021.111322","journal-title":"Mol Cell Endocrinol"},{"key":"5482_CR26","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/carcin\/bgy095","volume":"39","author":"J Remsik","year":"2018","unstructured":"Remsik J et al (2018) Trop-2 plasticity is controlled by epithelial-to-mesenchymal transition. Carcinogenesis 39:1411","journal-title":"Carcinogenesis"},{"issue":"2","key":"5482_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, Cortes J, Soria J-C, Curigliano G (2022) Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin 72(2):165\u2013182. https:\/\/doi.org\/10.3322\/caac.21705","journal-title":"CA Cancer J Clin"},{"key":"5482_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.pharmthera.2017.07.013","volume":"181","author":"PA Trail","year":"2018","unstructured":"Trail PA, Dubowchik GM, Lowinger TB (2018) Antibody drug conjugates for treatment of BC: novel targets and diverse approaches in ADC design. Pharmacol Ther 181:126\u2013142","journal-title":"Pharmacol Ther"},{"issue":"15_suppl","key":"5482_CR29","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1200\/JCO.2017.35.15_suppl.1075","volume":"35","author":"N Vidula","year":"2017","unstructured":"Vidula N, Yau C, Rugo HS (2017) Trop2 gene expression (Trop2e) in primary BC (BC): correlations with clinical and tumor characteristics. J Clin Oncol 35(15_suppl):1075. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.1075","journal-title":"J Clin Oncol"},{"issue":"11","key":"5482_CR30","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1007\/s11427-022-2240-6","volume":"66","author":"Y Wang","year":"2023","unstructured":"Wang Y, Yan Q, Fan C, Mo Y, Wang Y, Li X et al (2023) Overview and countermeasures of cancer burden in China. Science China Life Sciences 66(11):2515\u20132526","journal-title":"Science China Life Sciences"},{"issue":"1","key":"5482_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","volume":"13","author":"J Yu","year":"2020","unstructured":"Yu J, Song Y, Tian W (2020) How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol 13(1):45","journal-title":"J Hematol Oncol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05482-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05482-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05482-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:23:55Z","timestamp":1787621035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05482-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5482"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05482-8","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. As this is a review article, formal ethical approval was not required as per our institution\u2019s guidelines.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}